Kevin Chan

Kevin focuses on providing strategic patent portfolio development and intellectual property (IP) counseling for clients in the life sciences sector, including emerging biotech companies and investors. His work includes advising on patent prosecution, performing IP due diligence and freedom-to-operate analyses, and helping companies protect innovations and navigate complex IP landscapes worldwide.

Kevin has extensive experience with advanced technologies, including therapeutic antibodies and antibody-like molecules; immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) and T-cell receptor (TCR) platforms; gene therapies; viral delivery systems such as lentiviruses, adeno-associated viruses and oncolytic viruses; gene editing; and associated manufacturing processes. He also provides counsel on antibody discovery platforms and formulation technologies.

Before joining Cooley, Kevin worked with leading patent counseling groups where he managed and prosecuted patent portfolios worldwide and supported companies through all stages of development. His scientific background includes a PhD from the University of Toronto, where he studied genetic pathways involved in cell migration and neurodevelopment.

Kevin is fluent in Cantonese and Mandarin.